These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1458462)

  • 41. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
    Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
    Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
    Rowinsky EK; Long GS; Noe DA; Grochow LB; Bowling MK; Sartorius SE; Donehower RC
    Clin Cancer Res; 1997 Mar; 3(3):401-7. PubMed ID: 9815698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.
    Stevenson JP; DeMaria D; Reilly D; Purvis JD; Graham MA; Lockwood G; Drozd M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1999; 44(3):228-34. PubMed ID: 10453724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
    McKeage MJ; Raynaud F; Ward J; Berry C; O'Dell D; Kelland LR; Murrer B; Santabárabara P; Harrap KR; Judson IR
    J Clin Oncol; 1997 Jul; 15(7):2691-700. PubMed ID: 9215842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumors.
    Theriault RL; Cohen IA; Esparza L; Kowal C; Raber MN
    Cancer Chemother Pharmacol; 1993; 31(4):333-7. PubMed ID: 8422699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
    Dodion PF; de Valeriola D; Crespeigne N; Kantrowitz JD; Piccart M; Wery F; Kerger J; Egorin MJ; Forrest A; Bachur NR
    Ann Oncol; 1991 Sep; 2(8):589-96. PubMed ID: 1793726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
    Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
    Mancinelli A; D'Iddio S; Bisonni R; Graziano F; Lippe P; Calvani M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):19-26. PubMed ID: 16988826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of E7010.
    Yamamoto K; Noda K; Yoshimura A; Fukuoka M; Furuse K; Niitani H
    Cancer Chemother Pharmacol; 1998; 42(2):127-34. PubMed ID: 9654112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
    Joss RA; Kaplan S; Goldhirsch A; Sessa C; Brunner KW; Cavalli F
    Invest New Drugs; 1984; 2(3):297-304. PubMed ID: 6392147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
    Guillet P; Monjanel S; Nicoara A; Duffaud F; Lacarelle B; Bagarry-Liegey D; Durand A; Catalin J; Favre R
    Cancer Chemother Pharmacol; 1997; 40(2):143-9. PubMed ID: 9182836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
    Pagani O; Zucchetti M; Sessa C; de Jong J; D'Incalci M; De Fusco M; Kaeser-Fröhlich A; Hanauske A; Cavalli F
    Cancer Chemother Pharmacol; 1996; 38(6):541-7. PubMed ID: 8823496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ
    Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.